|
Reliability and regional specificity of glutathione and gamma-aminobutyric acid edited magnetic resonance spectroscopy in the human subcortex |
1R03TR004103-01 |
|
NCATS |
2022 |
|
Cdc42bpg signaling in arteriosclerosis and vascular fibrosis |
1R03TR004144-01 |
|
NCATS |
2022 |
|
Elucidating the roles of CACNA2D2 and CACNA2D3 in presynaptic regulation of mammalian synaptic function |
1R03TR004161-01 |
|
NCATS |
2022 |
|
Engineering Clinical Trials on a Chip for Dystrophin-Deficient Muscular Dystrophy |
4UH3TR003271-03 |
|
NCATS |
2022 |
|
Optimizing Muscular Dystrophy Clinical Trial Designs using Modeling and Simulation |
5R21TR004006-02 |
|
NCATS |
2022 |
|
PAR-18-953 (ASCOT-DMD) |
5R21TR004007-02 |
|
NCATS |
2022 |
|
Molecular Mechanism of the Parkinsons Disease-associated protein LRRK2 |
1R01AG075132-01A1 |
|
NIA |
2022 |
|
Developing a Prediction Model to Improve End‐of‐Life Prognostication and Hospice Referral in Parkinsons Disease |
1R21AG075524-01A1 |
|
NIA |
2022 |
|
Astrocyte NLRP3 inflammasome activation in Parkinsons disease |
5F30AG067643-03 |
|
NIA |
2022 |
|
Feasibility of Objective Measures and Outpatient Washout in Disease-Modifying Trials for Parkinsons Disease |
5K01AG066971-02 |
|
NIA |
2022 |